IGBA Calls For ‘Streamlining’ Of Global Biosimilars Process
Points To ‘Limited Value’ Of Efficacy Data; Urges Renewed Education Efforts
Executive Summary
The International Generic and Biosimilar medicines Association has called for a “streamlined” global biosimilar development and registration process, with a new policy paper highlighting the limited value of comparative efficacy clinical data at the same time as it urges renewed efforts on educating health care professionals.
You may also be interested in...
Global Harmonization Efforts Must Go Further
With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.
UK To Diverge On Biosimilar Data Requirements
The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.
UK To Diverge On Biosimilar Data Requirements
The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.